|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Naito S, Tomita Y, Rha SY, Uemura H, Oya
M, Song HZ, Zhong LH and Wahid MI: Kidney Cancer Working Group
report. Jpn J Clin Oncol. 40:(Suppl 1). i51–i56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
MacLennan S, Imamura M, Lapitan MC, Omar
MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G,
MacLennan SJ, et al: Systematic review of oncological outcomes
following surgical management of localised renal cancer. Eur Urol.
61:972–993. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dutcher JP, Fisher RI, Weiss G, Aronson F,
Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, et
al: Outpatient subcutaneous interleukin-2 and interferon-alpha for
metastatic renal cell cancer: Five-year follow-up of the cytokine
working group study. Cancer J Sci Am. 3:157–162. 1997.PubMed/NCBI
|
|
6
|
Negrier S, Escudier B, Lasset C, Douillard
JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau
M, et al: Recombinant human interleukin-2, recombinant human
interferon alfa-2a, or both in metastatic renal-cell carcinoma.
Groupe Francais d'Immunotherapie. N Engl J Med. 338:1272–1278.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA,
Kavina A, et al: Pazopanib in locally advanced or metastatic renal
cell carcinoma: Results of a randomized phase III trial. J Clin
Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Motzer RJ, Barrios CH, Kim TM, Falcon S,
Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha
SY, et al: Phase II randomized trial comparing sequential
first-line everolimus and second-line sunitinib versus first-line
sunitinib and second-line everolimus in patients with metastatic
renal cell carcinoma. J Clin Oncol. 32:2765–2772. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heng DY, Xie W, Regan MM, Harshman LC,
Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan
MH, et al: External validation and comparison with other models of
the international metastatic renal-cell carcinoma database
consortium prognostic model: A population-based study. Lancet
Oncol. 14:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heng DY, Xie W, Regan MM, Warren MA,
Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: Results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bromwich EJ, McArdle PA, Canna K, McMillan
DC, McNicol AM, Brown M and Aitchison M: The relationship between
T-lymphocyte infiltration, stage, tumour grade and survival in
patients undergoing curative surgery for renal cell cancer. Br J
Cancer. 89:1906–1908. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Crumley AB, McMillan DC, McKernan M,
McDonald AC and Stuart RC: Evaluation of an inflammation-based
prognostic score in patients with inoperable gastro-oesophageal
cancer. Br J Cancer. 94:637–641. 2006.PubMed/NCBI
|
|
16
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic
scores based on the systemic inflammatory response in patients with
inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujikawa K, Matsui Y, Oka H, Fukuzawa S
and Takeuchi H: Serum C-reactive protein level and the impact of
cytoreductive surgery in patients with metastatic renal cell
carcinoma. J Urol. 162:1934–1937. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bazzi WM, Tin AL, Sjoberg DD, Bernstein M
and Russo P: The prognostic utility of preoperative
neutrophil-to-lymphocyte ratio in localized clear cell renal cell
carcinoma. Can J Urol. 23:8151–8154. 2016.PubMed/NCBI
|
|
19
|
Hu K, Lou L, Ye J and Zhang S: Prognostic
role of the neutrophil-lymphocyte ratio in renal cell carcinoma: A
meta-analysis. BMJ Open. 5:e0064042015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Templeton AJ, Knox JJ, Lin X, Simantov R,
Xie W, Lawrence N, Broom R, Fay AP, Rini B, Donskov F, et al:
Change in neutrophil-to-lymphocyte ratio in response to targeted
therapy for metastatic renal cell carcinoma as a prognosticator and
biomarker of efficacy. Eur Urol. 70:358–364. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang GM, Zhu Y, Gu WJ, Zhang HL, Shi GH
and Ye DW: Pretreatment neutrophil-to-lymphocyte ratio predicts
prognosis in patients with metastatic renal cell carcinoma
receiving targeted therapy. Int J Clin Oncol. 21:373–378. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Argiles JM, Busquets S, Stemmler B and
López-Soriano FJ: Cancer cachexia: Understanding the molecular
basis. Nat Rev Cancer. 14:754–762. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McMillan DC, Scott HR, Watson WS, Preston
T, Milroy R and McArdle CS: Longitudinal study of body cell mass
depletion and the inflammatory response in cancer patients. Nutr
Cancer. 31:101–105. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
O'Gorman P, McMillan DC and McArdle CS:
Prognostic factors in advanced gastrointestinal cancer patients
with weight loss. Nutr Cancer. 37:36–40. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scott HR, McMillan DC, Crilly A, McArdle
CS and Milroy R: The relationship between weight loss and
interleukin 6 in non-small-cell lung cancer. Br J Cancer.
73:1560–1562. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scott HR, McMillan DC, Forrest LM, Brown
DJ, McArdle CS and Milroy R: The systemic inflammatory response,
weight loss, performance status and survival in patients with
inoperable non-small cell lung cancer. Br J Cancer. 87:264–267.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lamb GW, Aitchison M, Ramsey S, Housley SL
and McMillan DC: Clinical utility of the Glasgow Prognostic Score
in patients undergoing curative nephrectomy for renal clear cell
cancer: Basis of new prognostic scoring systems. Br J Cancer.
106:279–283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An
inflammation-based prognostic score (mGPS) predicts cancer survival
independent of tumour site: A Glasgow inflammation outcome study.
Br J Cancer. 104:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ramsey S, Lamb GW, Aitchison M, Graham J
and McMillan DC: Evaluation of an inflammation-based prognostic
score in patients with metastatic renal cancer. Cancer.
109:205–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McMillan DC, Crozier JE, Canna K, Angerson
WJ and McArdle CS: Evaluation of an inflammation-based prognostic
score (GPS) in patients undergoing resection for colon and rectal
cancer. Int J Colorectal Dis. 22:881–886. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen Z, Shao Y, Fan M, Zhuang Q, Wang K,
Cao W, Xu X and He X: Prognostic significance of preoperative
C-reactive protein: Albumin ratio in patients with clear cell renal
cell carcinoma. Int J Clin Exp Pathol. 8:14893–14900.
2015.PubMed/NCBI
|
|
32
|
Pichler M, Hutterer GC, Stoeckigt C,
Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A,
Mannweiler S, Pummer K and Zigeuner R: Validation of the
pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in
a large European cohort of renal cell carcinoma patients. Br J
Cancer. 108:901–907. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gunduz S, Mutlu H, Tural D, Yıldız Ö,
Uysal M, Coskun HS and Bozcuk H: Platelet to lymphocyte ratio as a
new prognostic for patients with metastatic renal cell cancer. Asia
Pac J Clin Oncol. 11:288–292. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z
and Xu J: Systemic inflammation score predicts postoperative
prognosis of patients with clear-cell renal cell carcinoma. Br J
Cancer. 113:626–633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jeon HG, Choi DK, Sung HH, Jeong BC, Seo
SI, Jeon SS, Choi HY and Lee HM: Preoperative prognostic
nutritional index is a significant predictor of survival in renal
cell carcinoma patients undergoing nephrectomy. Ann Surg Oncol.
23:321–327. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kinoshita A, Onoda H, Imai N, Iwaku A,
Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H and Matsushima M:
The C-reactive protein/albumin ratio, a novel inflammation-based
prognostic score, predicts outcomes in patients with hepatocellular
carcinoma. Ann Surg Oncol. 22:803–810. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wei XL, Wang FH, Zhang DS, Qiu MZ, Ren C,
Jin Y, Zhou YX, Wang DS, He MM, Bai L, et al: A novel
inflammation-based prognostic score in esophageal squamous cell
carcinoma: The C-reactive protein/albumin ratio. BMC Cancer.
15:3502015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jabs WJ, Busse M, Krüger S, Jocham D,
Steinhoff J and Doehn C: Expression of C-reactive protein by renal
cell carcinomas and unaffected surrounding renal tissue. Kidney
Int. 68:2103–2110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Robert F, Mills JR, Agenor A, Wang D,
DiMarco S, Cencic R, Tremblay ML, Gallouzi IE, Hekimi S, Wing SS
and Pelletier J: Targeting protein synthesis in a Myc/mTOR-driven
model of anorexia-cachexia syndrome delays its onset and prolongs
survival. Cancer Res. 72:747–756. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yoshida T, Tabony AM, Galvez S, Mitch WE,
Higashi Y, Sukhanov S and Delafontaine P: Molecular mechanisms and
signaling pathways of angiotensin II-induced muscle wasting:
Potential therapeutic targets for cardiac cachexia. Int J Biochem
Cell Biol. 45:2322–2332. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gordon BS, Kelleher AR and Kimball SR:
Regulation of muscle protein synthesis and the effects of catabolic
states. Int J Biochem Cell Biol. 45:2147–2157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Manne ND, Lima M, Enos RT, Wehner P,
Carson JA and Blough E: Altered cardiac muscle mTOR regulation
during the progression of cancer cachexia in the ApcMin/+ mouse.
Int J Oncol. 42:2134–2140. 2013.PubMed/NCBI
|
|
43
|
Nagineni CN, William A, Cherukuri A,
Samuel W, Hooks JJ and Detrick B: Inflammatory cytokines regulate
secretion of VEGF and chemokines by human conjunctival fibroblasts:
Role in dysfunctional tear syndrome. Cytokine. 78:16–19. 2016.
View Article : Google Scholar : PubMed/NCBI
|
